PyInvesting

Market research

X2S.F Sinopharm Group Co., Ltd

F EUR Healthcare

Latest close

1.833 —

As of 30 Oct 2026

Test a moving-average rule with historical data.

Market facts
Market cap
6B
P/E ratio
6.43
Analyst target
Not available
Dividend yield
38.%
Beta
0.46

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 6 months ago

Sinopharm Group Co., Ltd is currently in a long term uptrend where the price is trading 6.7% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.1.

Sinopharm Group Co., Ltd's total revenue sank by 0.0% to $111B since the same quarter in the previous year.

Its net income has dropped by 0.0% to $2B since the same quarter in the previous year.

Finally, its free cash flow grew by 9.0% to $37B since the same quarter in the previous year.

Based on the above factors, Sinopharm Group Co., Ltd gets an overall score of 3/5.